“This is that the initial study to demonstrate the practicableness and effectiveness of bidirectional therapy for downstaging at the start unresectable MPM [malignant serosa mesothelioma],” the authors wrote. “The study incontestible it's a well-tolerated and effective treatment.” According to the study, half the antecedently unresectable or borderline cases became eligible for surgery when bidirectional therapy, that LED to a extended overall median survival. “The aim of bidirectional therapy is to extend the native cytotoxic impact with the intent to extend the speed of complete surgical process,” the authors wrote. “Downsizing the extent of the serosa illness with AN economical surgical treatment represents a polar issue.”